Medscape: Merck's new COVID pill: 'Game-changer' or just one more tool?

UC infectious disease specialist says it's not a 'home run' but it is encouraging

The announcement from Merck on October 1 that it would federal regulators for emergency use authorization for its auspicious new COVID-19 pill, triggered a series of accolades. 

Medscape reported that former U.S. Food and Drug Administration chief Scott Gottlieb, MD, told CNBC the drug was "a profound game-changer." Top infectious disease expert Anthony Fauci, MD, called the early data "impressive." The World Health Organization termed it "certainly good news," while saying it awaits more data.

One of the experts quoted in the Medscape article was Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine. 

A man wearing a lab coat in a medical lab standing and gesturing with his left hand

Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Joe Fuqua II/UC Creative + Brand

"It's not exactly a home run, like penicillin for strep throat," says Fichtenbaum, who is investigating a similar pill for a rival company, Atea, partnering with Roche. 

"But it is encouraging," he said. "It will probably be an incremental improvement on what we have." The fact that it can be taken at home is a plus: "Anything we can do to keep people from getting sicker is a good thing."

Medscape reported that in addition to studying the drug in infected patients at high risk of severe illness and in those at typical risk, Pfizer launched a phase 2-3 study in late September that will enroll people who live in the same household as a person with a confirmed, symptomatic COVID-19 infection to see if the drug can prevent disease in those who have been exposed.

Atea and Roche's COVID pill, AT527, is in phase 3 trials as well.  AT527 is an inhibitor of polymerase, an enzyme many viruses have, to stop replications. Atea is evaluating the drug to reduce disease "burden" and for both pre- and postexposure prevention.

It may be necessary to target the coronavirus with more than one antiviral agent, said Fichtenbaum, a principal investigator for the AT527 trials. 

"Sometimes viruses require two or three active agents to control their replication," he said, citing information gleaned from other viral research, such as HIV. For control of HIV infection, a cocktail or combination of antivirals are often recommended.

That may well be the case for COVID-19, Fichtenbaum said. The goal would be to attack the virus at more than one pathway.

Read the entire story here.

Lead photo/Associated Press

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.